But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
But a lacklustre pipeline could stoke the need for deals.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.